Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study
Right heart failure is a major challenge in clinical practice. Soluble Suppression of Tumorigenicity-2 (sST2), a member of the interleukin-1-receptor family, may have clinical prognostic value. The aim of this study was to analyze whether sST2 correlates with signs of acute right heart decompensatio...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/23/7200 |
| _version_ | 1797399980405686272 |
|---|---|
| author | Victoria Dworok Valentin Hähnel Marwin Bannehr Vera Paar Christoph Edlinger Michael Lichtenauer Christian Butter Anja Haase-Fielitz |
| author_facet | Victoria Dworok Valentin Hähnel Marwin Bannehr Vera Paar Christoph Edlinger Michael Lichtenauer Christian Butter Anja Haase-Fielitz |
| author_sort | Victoria Dworok |
| collection | DOAJ |
| description | Right heart failure is a major challenge in clinical practice. Soluble Suppression of Tumorigenicity-2 (sST2), a member of the interleukin-1-receptor family, may have clinical prognostic value. The aim of this study was to analyze whether sST2 correlates with signs of acute right heart decompensation. This prospective single-center study included 50 patients admitted for clinical signs of predominant right heart decompensation. Signs of reduced blood supply to other organs (e.g., renal function parameter, troponin T, NT-proBNP), diuretics, and signs of venous congestion (inferior vena cava (IVC) diameter) with fluid retention (weight gain, peripheral edema) resulting from reduced RV function were analyzed. The degree of peripheral edema was defined as none, mild (5–6 mm depressible, regression in 15–60 s) or severe (>7 mm depressible, regression in 2–3 min). sST2 levels were measured at the day of hospitalization. A total of 78.7% showed severe peripheral edema. The median concentration of sST2 was 35.2 ng/mL (25.–75. percentiles 17.2–46.7). sST2 is correlated with the peripheral edema degree (rSpearman = 0.427, <i>p</i> = 0.004) and the diameter of IVC (r = 0.786, <i>p</i> = 0.036), while NT-proBNP (r = 0.114, <i>p</i> = 0.456), troponin T (r = 0.123, <i>p</i> = 0.430), creatinine-based eGFR (r = −0.207, <i>p</i> = 0.195), or cystatin C-based eGFR (r = −0.032, <i>p</i> = 0.839) did not. sST2, but no other established marker, is correlated with peripheral and central fluid status in patients with decompensated right heart failure. |
| first_indexed | 2024-03-09T01:48:56Z |
| format | Article |
| id | doaj.art-73d75a57e2894711b2c840c8a56c6a59 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T01:48:56Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-73d75a57e2894711b2c840c8a56c6a592023-12-08T15:18:32ZengMDPI AGJournal of Clinical Medicine2077-03832023-11-011223720010.3390/jcm12237200Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational StudyVictoria Dworok0Valentin Hähnel1Marwin Bannehr2Vera Paar3Christoph Edlinger4Michael Lichtenauer5Christian Butter6Anja Haase-Fielitz7Department of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, GermanyDepartment of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, GermanyDepartment of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, GermanyClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, GermanyClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, GermanyDepartment of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, GermanyRight heart failure is a major challenge in clinical practice. Soluble Suppression of Tumorigenicity-2 (sST2), a member of the interleukin-1-receptor family, may have clinical prognostic value. The aim of this study was to analyze whether sST2 correlates with signs of acute right heart decompensation. This prospective single-center study included 50 patients admitted for clinical signs of predominant right heart decompensation. Signs of reduced blood supply to other organs (e.g., renal function parameter, troponin T, NT-proBNP), diuretics, and signs of venous congestion (inferior vena cava (IVC) diameter) with fluid retention (weight gain, peripheral edema) resulting from reduced RV function were analyzed. The degree of peripheral edema was defined as none, mild (5–6 mm depressible, regression in 15–60 s) or severe (>7 mm depressible, regression in 2–3 min). sST2 levels were measured at the day of hospitalization. A total of 78.7% showed severe peripheral edema. The median concentration of sST2 was 35.2 ng/mL (25.–75. percentiles 17.2–46.7). sST2 is correlated with the peripheral edema degree (rSpearman = 0.427, <i>p</i> = 0.004) and the diameter of IVC (r = 0.786, <i>p</i> = 0.036), while NT-proBNP (r = 0.114, <i>p</i> = 0.456), troponin T (r = 0.123, <i>p</i> = 0.430), creatinine-based eGFR (r = −0.207, <i>p</i> = 0.195), or cystatin C-based eGFR (r = −0.032, <i>p</i> = 0.839) did not. sST2, but no other established marker, is correlated with peripheral and central fluid status in patients with decompensated right heart failure.https://www.mdpi.com/2077-0383/12/23/7200Soluble Suppression of Tumorigenicity 2 (sST2)biomarkerNT-proBNPdecompensated heart failure |
| spellingShingle | Victoria Dworok Valentin Hähnel Marwin Bannehr Vera Paar Christoph Edlinger Michael Lichtenauer Christian Butter Anja Haase-Fielitz Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study Journal of Clinical Medicine Soluble Suppression of Tumorigenicity 2 (sST2) biomarker NT-proBNP decompensated heart failure |
| title | Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study |
| title_full | Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study |
| title_fullStr | Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study |
| title_full_unstemmed | Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study |
| title_short | Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study |
| title_sort | soluble suppression of tumorigenicity 2 sst2 in patients with predominantly decompensated right heart failure a prospective observational study |
| topic | Soluble Suppression of Tumorigenicity 2 (sST2) biomarker NT-proBNP decompensated heart failure |
| url | https://www.mdpi.com/2077-0383/12/23/7200 |
| work_keys_str_mv | AT victoriadworok solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT valentinhahnel solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT marwinbannehr solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT verapaar solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT christophedlinger solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT michaellichtenauer solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT christianbutter solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy AT anjahaasefielitz solublesuppressionoftumorigenicity2sst2inpatientswithpredominantlydecompensatedrightheartfailureaprospectiveobservationalstudy |